Who
Douglas S. Ingram
Director
Company insider
Files Form 4 as: Director, Relay Therapeutics; Director, Arrowhead Pharmaceuticals; Chief Executive Officer, Sarepta Therapeutics; Director, Endo International; Vice Chairman, Skye Bioscience; President, Allergan; Director, Volcom.
In numbers
- Trades disclosed
- 149
- Buys
- 9
- Sells
- 11
- Bought
- $14.6M
- Sold
- $33.4M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 6 Feb 2006
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,947 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,947 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,819 at $0.00 | filing |
| 7 Dec 2025filed 9 Dec 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Dec 2025filed 9 Dec 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Dec 2025filed 9 Dec 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —73,001 at $0.00 | filing |
| 7 Dec 2025filed 9 Dec 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —96,541 at $0.00 | filing |
| 7 Dec 2025filed 9 Dec 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —269,542 at $0.00 | filing |
| 6 Jun 2025filed 6 Jun 2025 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —136,681 at $0.00 | filing |
| 6 Feb 2025filed 7 Feb 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $771K38,396 at $20.09 | filing |
| 3 Jun 2024filed 5 Jun 2024 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —102,225 at $0.00 | filing |
| 3 Nov 2023filed 6 Nov 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $792K10,081 at $78.57 | filing |
| 3 Nov 2023filed 6 Nov 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $881K11,060 at $79.70 | filing |
| 3 Nov 2023filed 6 Nov 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $312K3,884 at $80.33 | filing |
| 3 Nov 2023filed 6 Nov 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $16K200 at $81.26 | filing |
| 31 May 2023filed 1 Jun 2023 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,055 at $0.00 | filing |
| 27 May 2022filed 27 May 2022 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,597 at $0.00 | filing |
| 17 Nov 2021filed 17 Nov 2021 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.0M25,026 at $79.94 | filing |
| 26 Jun 2021filed 28 Jun 2021 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $1.4M17,812 at $80.40 | filing |
| 19 May 2021filed 21 May 2021 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
News
Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)SRPT · tickerreport.com · 11 Oct 2026Head-To-Head Comparison: Krystal Biotech (NASDAQ:KRYS) and Relay Therapeutics (NASDAQ:RLAY)RLAY · tickerreport.com · 11 Oct 2026Relay Therapeutics (NASDAQ:RLAY) Stock: Insider Sanjiv Patel Sells 48,199 SharesRLAY · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Douglas S. Ingram; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.